Reumatologia Clinica最新文献

{"title":"Cognitive dysfunction in systemic lupus erythematosus: Insights from a two-year longitudinal study in a Brazilian cohort","authors":"Eduarda Scoto Dias ,&nbsp;José Henrique Tercziany Vanzin ,&nbsp;Eduardo Augusto Borba ,&nbsp;Mahara Freitas dos Santos ,&nbsp;Thiago Alberto F.G. dos Santos ,&nbsp;Thelma Skare ,&nbsp;Renato Nisihara","doi":"10.1016/j.reuma.2025.501941","DOIUrl":"10.1016/j.reuma.2025.501941","url":null,"abstract":"<div><h3>Objectives</h3><div>The objective of this study was to examine cognitive dysfunction in a Brazilian sample of SLE patients for two years.</div></div><div><h3>Methods</h3><div>A sample of 50 individuals with SLE was assessed at baseline for epidemiological and treatment data, disease activity by SLEDAI 2K (SLE disease activity 2000), cumulative damage by SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), depression by CES-D (Center for Epidemiological Studies-Depression) and cognitive function through MoCA (Montreal Cognitive Assessment). The same assessment was repeated after two years.</div></div><div><h3>Results</h3><div>The prevalence of cognitive impairment at baseline was 68%. The baseline cognitive assessment showed impairment in visuospatial/executive function (<em>p</em> <!-->=<!--> <!-->0.002), naming (<em>p</em> <!-->=<!--> <!-->0.04), attention (<em>p</em> <!-->&lt;<!--> <!-->0.0001) and delayed recall (<em>p</em> <!-->&lt;<!--> <!-->0.0001). The median MoCA results did not change in two years (<em>p</em> <!-->=<!--> <!-->0.45), but 6 individuals (12%) that had normal cognitive function at baseline developed mild cognitive impairment and two (4%) that had mild cognitive impairment, improved. When considering the MoCA domains the only significant difference was improvement in abstraction (<em>p</em> <!-->=<!--> <!-->0.001). No correlations between MoCA delta (difference between second and first value) and delta SLEDAI, delta SLICC and delta CES-D were found (all with <em>p</em> <!-->&gt;<!--> <!-->0.05). Also, no associations were found with used treatment or autoantibodies profile.</div></div><div><h3>Conclusions</h3><div>Cognitive dysfunction in SLE is dynamic and may require periodic re-assessments. Changes in cognition were not associated with disease activity, depression or cumulative damage in this sample.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501941"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcultural adaptation and validation of the Transition Readiness Assessment Questionnaire (TRAQ) into Mexican Spanish","authors":"Sara G. Rosiles-De la Garza ,&nbsp;Ingris Pelaez-Ballestas ,&nbsp;Fernando García-Rodríguez ,&nbsp;Ana V. Villarreal-Treviño ,&nbsp;Elisa L. Dávila-Sotelo ,&nbsp;Leonor G. Hinojosa-Amaya ,&nbsp;Jesús E. Treviño-Alvarado ,&nbsp;Óscar González-Llano ,&nbsp;Laura Villarreal-Matínez ,&nbsp;Yajaira V. Jiménez-Antolínez ,&nbsp;Julia E. Colunga-Pedraza ,&nbsp;Nadina E. Rubio-Pérez","doi":"10.1016/j.reuma.2025.501917","DOIUrl":"10.1016/j.reuma.2025.501917","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of the present study was to translate and perform a transcultural adaptation and validation of the TRAQ into Mexican Spanish.</div></div><div><h3>Methodology</h3><div>Transversal and observational study. First, the TRAQ was translated and transculturally adapted into Mexican Spanish. Then, the adapted TRAQ was administered to patients of any gender between 12 and 21 years of age and a chronic disease diagnosis. Correlation matrices for the questionnaire were obtained and their reliability was measured through homogeneity and internal consistency.</div></div><div><h3>Results</h3><div>The TRAQ was successfully translated and transculturally adapted into Mexican Spanish. After this, a pilot test of the questionnaire was performed with 40 patients. Lastly, the final validation phase was undertaken with 141 patients, with a median age of 13.9 years. The internal consistency analysis revealed a Cronbach's alpha global evaluation of 0.76, while the results organized through domains varied from 0.47 to 0.60.</div></div><div><h3>Conclusions</h3><div>The translated and transculturally adapted TRAQ revealed a good internal consistency, similar to other transcultural adoptions previously described in the medical literature. This process will allow us to ensure cultural and linguistic relevance for Mexican patients, particularly given the unique socio-cultural context of the Mexican population.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501917"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of a checklist for the control of the disease activity in patients with axial spondyloarthritis","authors":"Raquel Almodóvar ,&nbsp;Elia Pérez-Fernández ,&nbsp;Marta Valero ,&nbsp;Virginia Villaverde ,&nbsp;Laura González ,&nbsp;Beatriz Joven Ibáñez ,&nbsp;Eva Tomero Muriel ,&nbsp;Alejandro Prada Ojeda ,&nbsp;M.a Teresa Navio ,&nbsp;Laura Cebrián Méndez ,&nbsp;Leticia Lojo ,&nbsp;Ramón Mazzucchelli ,&nbsp;Pedro Zarco Montejo","doi":"10.1016/j.reuma.2025.501918","DOIUrl":"10.1016/j.reuma.2025.501918","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the effectiveness of a checklist for disease activity and comorbidity control in patients with axial spondyloarthritis (axSpA).</div></div><div><h3>Method</h3><div>A quasi-experimental retrospective multicentre pre-post intervention study was carried out in Spain between 2016 and 2022. Improvement in disease activity and comorbidity status was determined before and after the implementation of a checklist control in patients diagnosed with axSpA. Disease activity was determined by means of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) levels. Comorbidity status was determined by analysing several risk factors (blood pressure, body weight, blood test, etc.). An analysis of variance with mixed models between pre and post collected values was performed. The change in therapeutic level and disease status (low activity, remission) was determined by means of the Mc-Nemar asymmetry test.</div></div><div><h3>Results</h3><div><span><span>A total of 108 patients with axSpA were included in the study. After checklist implementation, a statistically significant reduction in </span>BASDAI of 0.44 (95%CI: 0.06–0.82, </span><em>p</em> <!-->=<!--> <!-->0.023) and a significant reduction of 3.82<!--> <!-->mg/L (<em>p</em> <!-->=<!--> <!-->0.001) in CRP was observed. Besides, an increase in uricemia of 0.24<!--> <!-->mg/dl was found (95%CI: 1.49–6.14, <em>p</em> <!-->=<!--> <!-->0.001), while no other statistically significant change in comorbidities was observed.</div></div><div><h3>Conclusions</h3><div>The implementation of a checklist in daily clinical practice leads to a significant improvement in the control of disease activity in patients with axSpA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501918"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index","authors":"Juan José de Agustin ,&nbsp;Gustavo Adolfo Añez ,&nbsp;Delia Reina ,&nbsp;Sergi Heredia ,&nbsp;Julio Ramirez ,&nbsp;Andrea Mireya Cuervo ,&nbsp;Jesus Rodriguez ,&nbsp;Carmen Moragues ,&nbsp;Patricia Moya ,&nbsp;Ana Maria Laiz Alonso ,&nbsp;Mireia Moreno ,&nbsp;Marta Arevalo ,&nbsp;Manel Pujol ,&nbsp;Georgina Salvador ,&nbsp;Noemi Busquets ,&nbsp;Andres Ponce ,&nbsp;Maria Pascual Pastor","doi":"10.1016/j.reuma.2025.501921","DOIUrl":"10.1016/j.reuma.2025.501921","url":null,"abstract":"<div><h3>Background</h3><div>Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast. Primary objective: 20% reduction in the US index (UIC) at 12 months.</div></div><div><h3>Methodology</h3><div>Multicenter, prospective, open-label study. Patients with PsA (≥2 swollen joints) and ≥2 US synovitis in joints and ≥1 US enthesitis at screening were recruited. Follow-up was 52 weeks (baseline and 1, 6, 9, 12 months). US (joint, tendon, and entheses), clinical (SJC, TJC, LEI, PGA, PtGA), and biological (ESR and CRP) parameters were recorded.</div></div><div><h3>Results</h3><div>48 patients were evaluated, 46 were included in the follow-up and 26 completed the 52-week study. The primary endpoint was achieved, with reductions of up to 40%. All clinical and ultrasound variables decreased significantly after 12 months. 75 adverse events (AEs) were recorded in 33 patients, and only one serious event (SAE). Reasons for withdrawal included AEs (6 patients), lack of efficacy (8 patients), and other reasons (loss to follow-up, withdrawal of consent) for 6 patients.</div></div><div><h3>Conclusions</h3><div>Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501921"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Interacciona la microbiota humana con el tratamiento inmunosupresor de las enfermedades reumatológicas autoinmunes sistémicas? Revisión sistemática","authors":"Noemí Franco-Domingo ,&nbsp;Patricia Saiz-López ,&nbsp;Loreto Carmona-Ortells","doi":"10.1016/j.reuma.2025.501938","DOIUrl":"10.1016/j.reuma.2025.501938","url":null,"abstract":"<div><h3>Objective</h3><div>To collect and analyse studies evaluating the interaction between the human microbiota (HM) and immunosuppressive (IS) treatments for systemic autoimmune rheumatological diseases (ARDs), and their impact on the disease.</div></div><div><h3>Methods</h3><div>A systematic review was performed based on an electronic search strategy in Medline, Embase, and Cochrane Library (inception-02/2024). We included papers studying the interaction of HM and IS treatments in adult patients with ARDs in which parameters of diversity and taxonomic composition were measured. We excluded spondyloarthritis for which more extensive knowledge is available. Studies of any language were allowed, prioritising clinical trials but also including observational longitudinal prospective and retrospective, and case-control studies.</div></div><div><h3>Results</h3><div>Of 2570 papers identified, 20 were included (15 from rheumatoid arthritis, 3 from systemic lupus erythematosus, 1 from primary Sjögren's syndrome and 1 from systemic sclerosis), overall, with a moderate risk of bias. The paucity of studies and niche specificity limited the study to the gut microbiota. A trend towards decreased diversity and compositional changes in gut microbiota and partial restitution in patients responding to IS treatment was identified. The heterogeneity observed in the design and outcome measures of the studies precluded a metaanalysis; however, the results point to a possible relationship between HM alterations and response to IS treatments in ARDs.</div></div><div><h3>Conclusions</h3><div>Available studies suggest a potential association between the HM and the response to IS therapies in ARDs. However, the overall moderate quality of evidence and substantial methodological heterogeneity limit the strength of combined conclusions. Standardization of microbiota-related studies is needed to enable data integration and support more robust inferences.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501938"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis”","authors":"Sarah Aijaz ,&nbsp;Raveen Muzaffer ,&nbsp;Muhammad Zarrar ,&nbsp;Zauha Fawad Memon","doi":"10.1016/j.reuma.2025.501914","DOIUrl":"10.1016/j.reuma.2025.501914","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 6","pages":"Article 501914"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guía de práctica clínica para el tratamiento de la espondiloartritis axial y la artritis psoriásica. ESPOGUÍA 2024","authors":"Juan D. Cañete ,&nbsp;Petra Díaz del Campo Fontecha ,&nbsp;en nombre del Grupo Elaborador de la ESPOGUÍA","doi":"10.1016/j.reuma.2025.501892","DOIUrl":"10.1016/j.reuma.2025.501892","url":null,"abstract":"<div><div>The important advances in the area of therapeutic interventions and the time elapsed have justified the complete update of the Clinical practice guideline on the treatment of axial spondyloarthritis and psoriatic arthritis (ESPOGUIA2017). Methodologically, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system has been incorporated, which allows the quality or certainty of the evidence to be assessed for each outcome of interest, previously prioritized by the drafting group and which structures the process of formulating recommendations explicitly. Thus, an updated clinical practice guideline has been developed to serve as a reference in the management of spondyloarthritis, to contribute to reduce unjustified variability, and to reinforce the importance of bringing clinical practice closer to the best available scientific evidence.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 6","pages":"Article 501892"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residence at high altitude as a risk factor for high probability of pulmonary hypertension in patients with systemic sclerosis: A case–control study","authors":"Luis Javier Cajas ,&nbsp;Julia Recalde Reyes ,&nbsp;Javier Alejandro Correa ,&nbsp;Wilder Carvajal ,&nbsp;Carolina Torres ,&nbsp;José S. Cortés","doi":"10.1016/j.reuma.2025.501899","DOIUrl":"10.1016/j.reuma.2025.501899","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigated the association between high-altitude residence (&gt;2500<!--> <!-->m above sea level) and the presence of high probability of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc).</div></div><div><h3>Methods</h3><div>A retrospective case–control study was conducted with 368 patients diagnosed with SSc at the rheumatology outpatient clinic of a university hospital in Bogotá, Colombia. Patients were divided into two groups based on the presence of high probability of PH. Clinical, demographic, and high-altitude residence data were collected and analyzed. A multiple logistic regression model was used to control confounding variables.</div></div><div><h3>Results</h3><div>Patients residing at high altitudes had a significantly greater risk of presenting high probability of PH than those living at lower altitudes did (odds ratio: 2.0). Other significant factors included the diffuse cutaneous subtype of SSc and the presence of interstitial lung disease.</div></div><div><h3>Discussion</h3><div>High-altitude residence is a potential risk factor for presenting high probability of PH in SSc patients, warranting closer monitoring and tailored management in these populations. Further studies are warranted to confirm these findings.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 6","pages":"Article 501899"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoniquia inducida por mepacrina","authors":"Begoña de Escalante Yangüela ,&nbsp;Miguel García Gil ,&nbsp;Juan Vallejo Grijalba ,&nbsp;Cilia Peralta Ginés","doi":"10.1016/j.reuma.2025.501911","DOIUrl":"10.1016/j.reuma.2025.501911","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 6","pages":"Article 501911"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradoxical reaction after switching between adalimumab biosimilars in a patient with psoriatic arthritis","authors":"Mariano F. Palatnik ,&nbsp;Emilce S. Fonseca ,&nbsp;María Lorena Brance","doi":"10.1016/j.reuma.2025.501913","DOIUrl":"10.1016/j.reuma.2025.501913","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 6","pages":"Article 501913"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}